$100 Invested In Eli Lilly 5 Years Ago Would Be Worth This Much Today
Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 24.56% on an annualized basis…
US Stocks’ Resilience Faces Test As Traders Await Flurry Of Economic Data: Fed May ‘Surprise To The Upside’ On Rates Again In 2023, Says Analyst
The resilient market faces another test on Thursday, as traders get to digest another set of economic data and a few Fed speeches. The index futures pointed to a cautious start on Thursday.
Cues From Wednesday’s Trading:
Biggest US Pension Bulks Up On Tesla, Apple, And These Big Techs: How CalPERS Shuffled Its Portfolio In Q4
California Public Employees’ Retirement System, aka CalPERS, the biggest pension fund in the U.S., recently filed its 13F for the fourth quarter ended Dec. 30, with the SEC.
Here’s How Much $100 Invested In Eli Lilly 10 Years Ago Would Be Worth Today
Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 10.17% on an annualized basis…
Analyst Ratings for Eli Lilly
Eli Lilly (NYSE:LLY) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $455
Morgan Stanley analyst Terence Flynn maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $440 to $455.
Eli Lilly Posts Weaker Q4 Sales On Slower Demand For Its COVID-19 Treatment, Overshadowing Annual Guidance
Eli Lilly And Co (NYSE:LLY) has reported Q4 sales of $7.30 billion, down 9% Y/Y, missing the consensus of $7.33…
Eli Lilly Raised FY23 Adjusted EPS Outlook from $8.10-$8.30 To $8.35 to $8.55 Versus Consensus of $8.28
The company reaffirms 2023 sales guidance at $30.3-$30.8 billion compared to the consensus of $30.55 billion
February PDUFA Catalysts Biotech Investors Must Know: Sanofi’s Bleeding Disorder Drug, Regeneron’s Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new molecular entities for the year.
FDA Gives Conditional Approval For Eli Lilly’s Drug For Rare Blood Cancer
The FDA approved Eli Lilly And Co’s (NYSE:LLY) Jaypirca (pirtobrutinib) for adult patients with relapsed or refractory mantle cell lymphoma (MCL)…